A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Phesgo® Biosimilar HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Qi Jin
- Numero di telefono: 86 159 5516 0489
- Email: Qi_jin@henlius.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Voluntary participation in the clinical study and signed the Informed Consent Form (ICF).
- Male or female aged ≥ 18 years old at the time of signing the ICF;
- Histologically confirmed invasive breast cancer, stage II-IIIC, Human Epidermal Growth Factor Receptor 2 (HER2) positive confirmed by central laboratory.
- Participants agree to undergo surgery while meeting the criteria for surgery after neoadjuvant therapy.
- Left ventricular ejection fraction (LVEF) at baseline ≥ 55%.
- An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
- Adequate major organ functions.
- Women with child-bearing potential have a negative result of serum pregnancy test at screening period (within 7 days prior to the first dose) or if they are infertile, non- lactating, reproduction-age men and women following highly effective contraceptive measures until 7 months after last dose.
Exclusion Criteria:
- Stage IV breast cancer, bilateral breast cancer, or multicentric breast cancer.
- History of other malignancy within 5 years.
- Prior systemic therapy for breast cancer treatment or radiotherapy.
- Patients with a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) who have received systemic therapy or radiotherapy to the ipsilateral breast.
- Patients who have undergone excision biopsy of the primary tumor and/or axillary lymph nodes or lymph node dissection.
- Have severe heart disease or medical conditions.
- Participants with viral hepatitis or those with autoimmune hepatitis, sclerosing cholangitis, or liver cirrhosis.
- Human Immunodeficiency Virus (HIV) infection, HIV antibody positive.
- Daily use of corticosteroid treatment is required.
- Sensitivity to any study medications or any of its ingredients or excipients.
- Participants who underwent any major surgery within 28 days prior to the first dose. Or participants who have received local radiotherapy, radiofrequency ablation, or interventional therapy within 2 weeks prior to the first dose.
- Received another interventional clinical trial therapy within 4 weeks prior to enrollment in the study, or intentionally participated in another interventional clinical trial during the entire study period.
- Severe, uncontrolled systemic diseases that may currently interfere with the therapeutic plan.
- Any other conditions which are inappropriate for the study in the opinion of the investigator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: HLX319
The regimen in the experimental group is HLX319 in combination with docetaxel and carboplatin.
|
HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
|
Comparatore attivo: EU-Phesgo®
The regimen in the control group is EU-Phesgo® in combination with docetaxel and carboplatin.
|
EU-Phesgo® is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Peak concentration (Cmax)
Lasso di tempo: up to 180 days
|
Peak concentration after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from 0 to 21 days (AUC0-21d)
Lasso di tempo: up to 180 days
|
Area under the serum drug concentration-time curve from 0 to 21 days after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Steady-state peak concentration (Cmax,ss)
Lasso di tempo: up to 180 days
|
The steady-state peak concentration after multiple doses administration in Cycle 4.
|
up to 180 days
|
|
Steady-state area under the serum drug concentration-time curve within a dosing interval (AUCss)
Lasso di tempo: up to 180 days
|
Steady-state area under the serum drug concentration-time curve within a dosing interval after multiple doses administration in Cycle 4.
|
up to 180 days
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Trough concentration (Ctrough)
Lasso di tempo: up to 180 days
|
Trough concentration after a single dose administration
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from time 0 to infinity (AUC0-inf)
Lasso di tempo: up to 180 days
|
Area under the serum drug concentration-time curve from time 0 to infinity after a single dose administration
|
up to 180 days
|
|
Percentage of extrapolated area in the total AUC (%AUCex)
Lasso di tempo: up to 180 days
|
Percentage of extrapolated area in the total AUC after a single dose administration
|
up to 180 days
|
|
Time to peak concentration (Tmax)
Lasso di tempo: up to 180 days
|
time to peak concentration after a single dose administration
|
up to 180 days
|
|
Elimination half-life (T1/2)
Lasso di tempo: up to 180 days
|
elimination half-life after a single dose administration
|
up to 180 days
|
|
Total clearance (CL/F)
Lasso di tempo: up to 180 days
|
total clearance after a single dose administration
|
up to 180 days
|
|
Terminal phase distribution volume (Vz/F)
Lasso di tempo: up to 180 days
|
terminal phase distribution volume after a single dose administration
|
up to 180 days
|
|
Mean residence time (MRT)
Lasso di tempo: up to 180 days
|
mean residence time after a single dose administration
|
up to 180 days
|
|
Steady-state trough concentration (Ctrough,ss)
Lasso di tempo: up to 180 days
|
steady-state trough concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Average steady-state concentration (Caverage,ss)
Lasso di tempo: up to 180 days
|
average steady-state concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state time to peak concentration (Tmax,ss)
Lasso di tempo: up to 180 days
|
steady-state time to peak concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Elimination half-life (T1/2,ss)
Lasso di tempo: up to 180 days
|
elimination half-life after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state volume of distribution (Vss/F)
Lasso di tempo: up to 180 days
|
steady-state volume of distribution after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state total clearance (CLss/F)
Lasso di tempo: up to 180 days
|
steady-state total clearance after multiple doses administration in Cycle 4
|
up to 180 days
|
|
accumulation ratio based on Cmax (RCmax)
Lasso di tempo: up to 180 days
|
accumulation ratio based on Cmax after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Accumulation ratio based on AUC (RAUC)
Lasso di tempo: up to 180 days
|
accumulation ratio based on AUC after multiple doses administration in Cycle 4
|
up to 180 days
|
|
The total pathological complete response (tpCR) rate assessed by the investigator
Lasso di tempo: up to 180 days
|
up to 180 days
|
|
|
Breast pathologic complete response (bpCR) rate assessed by the investigator
Lasso di tempo: up to 180 days
|
up to 180 days
|
|
|
Objective response rate (ORR) assessed by the investigator
Lasso di tempo: up to 180 days
|
according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
|
up to 180 days
|
|
Incidence and severity of adverse events (AEs)
Lasso di tempo: up to 180 days
|
severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0
|
up to 180 days
|
|
Number of participants with abnormal vital signs
Lasso di tempo: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal physical examination findings
Lasso di tempo: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal Laboratory tests results
Lasso di tempo: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal 12-lead ECG readings
Lasso di tempo: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Positivity rates of anti-drug antibodies (ADA)
Lasso di tempo: up to 180 days
|
up to 180 days
|
|
|
Positivity rates of neutralizing antibodies (NAb)
Lasso di tempo: up to 180 days
|
up to 180 days
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HLX319-BC001
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .